LAX.SH
JUPITER LIFE LINE HOSP L·HOSPITALS 47.35·Healthcare Services Companies
Price
243.05
-1.38%52W Range
Market Cap
₹7,967.91 Cr
Traded: ₹1.67 Cr (0.02%) 0.0x
Free Float: ₹784.84 Cr (0.21% of FF traded)
Volume · 60D trend
68.94 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +17.0% | +16.0% | -- | -- | Decelerating |
| Return | -- | -- | -- | +16.0% | -- | -- |
| Profit | -- | +143.0% | +37.0% | -- | -1.0% | Decelerating |
| Sales | -- | +25.0% | +19.0% | -- | +15.0% | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 411 | 388 | 365 | 394 | 353 | 337 | 333 | 335 | 289 | 291 | 273 | 263 | 243 | 242 | 228 |
| Expenses | 332 | 299 | 282 | 301 | 275 | 257 | 256 | 257 | 223 | 228 | 211 | 202 | 190 | 191 | 183 |
| Operating Profit | 79 | 89 | 83 | 92 | 78 | 80 | 76 | 78 | 65 | 63 | 62 | 61 | 53 | 52 | 45 |
| Other Income | 11 | 11 | 3 | 11 | 13 | 7 | 7 | 7 | 7 | 10 | 8 | 3 | 4 | 1 | 2 |
| Interest | 13 | 9 | 8 | 8 | 8 | 6 | 3 | 1 | 1 | 1 | 1 | 12 | 12 | 11 | 11 |
| Depreciation | 26 | 23 | 22 | 21 | 21 | 18 | 14 | 14 | 11 | 10 | 11 | 11 | 11 | 10 | 10 |
| Profit Before Tax | 51 | 68 | 57 | 74 | 62 | 63 | 67 | 70 | 60 | 62 | 58 | 41 | 34 | 32 | 27 |
| Tax % | 26.0% | 26.0% | 25.0% | 23.0% | 29.0% | 28.0% | 22.0% | 26.0% | 26.0% | 27.0% | 25.0% | 19.0% | -60.0% | 51.0% | 101.0% |
| Net Profit | 38 | 50 | 42 | 57 | 44 | 45 | 52 | 52 | 45 | 45 | 44 | 34 | 54 | 16 | 0 |
| Exceptional Items | 0 | 2 | -6 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | -0 | -1 | -1 | -2 | 0 |
| EPS (Rs) | 1.1 | 1.5 | 1.3 | 1.8 | 1.3 | 1.4 | 1.6 | 1.6 | 1.4 | 1.4 | 1.3 | 1.0 | 1.9 | 2.8 | -0.1 |
| Sales Growth (YoY) | -- | 15.2% | 9.8% | 17.5% | 22.3% | 15.5% | 22.1% | 27.3% | 18.6% | 20.3% | 19.4% | 18.9% | 21.3% | -- | -- |
| Sales Growth (QoQ) | -- | 6.3% | -7.4% | 11.6% | 4.8% | 1.2% | -0.6% | 15.9% | -0.7% | 6.6% | 3.8% | 8.2% | 0.4% | 6.1% | -- |
| OP Growth (YoY) | 1.3% | 11.3% | 9.2% | 17.9% | 20.0% | 27.0% | 22.6% | 27.9% | 22.6% | 21.2% | 37.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -11.2% | 7.2% | -9.8% | 17.9% | -2.5% | 5.3% | -2.6% | 20.0% | 3.2% | 1.6% | 1.6% | 15.1% | 1.9% | 15.6% | -- |
| Profit Growth (YoY) | -- | 9.0% | -9.0% | 11.0% | -1.0% | 4.0% | 19.0% | 51.0% | -19.0% | 158.0% | 11621.0% | 26.0% | 80.0% | -- | -- |
| EPS Growth (YoY) | -- | 11.2% | -18.3% | 11.0% | -1.3% | 0.3% | 19.2% | 53.3% | -29.0% | 146.2% | 9614.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 18.0% | -25.8% | 30.8% | -2.9% | -13.2% | 0.8% | 16.2% | -1.3% | 3.1% | 29.6% | -46.2% | 242.3% | 4085.7% | -- |
| OP Margin | -- | 22.9% | 22.7% | 23.4% | 22.1% | 23.7% | 22.8% | 23.3% | 22.5% | 21.6% | 22.7% | 23.2% | 21.8% | 21.5% | 19.7% |
| Net Margin | -- | 12.9% | 11.5% | 14.5% | 12.5% | 13.3% | 15.6% | 15.5% | 15.6% | 15.5% | 16.1% | 12.9% | 22.2% | 6.6% | 0.0% |
| Material Cost % | 19.5% | 19.0% | 18.9% | 18.7% | 20.0% | 20.0% | 19.8% | 19.7% | 17.4% | 18.1% | 17.6% | 17.5% | 17.4% | 18.0% | 18.2% |
| Employee Cost % | 18.1% | 17.5% | 17.4% | 16.1% | 17.5% | 17.1% | 17.5% | 16.8% | 17.8% | 17.7% | 18.4% | 16.4% | 18.6% | 17.0% | 18.7% |
| P/S | 5.11 | 7.25 | 6.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 42.49 | 11.20 | 46.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.16 | 7.03 | 5.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Jupiter Life Line Hospitals Limited ('JLHL/Company') has entered into hypothecation agreement with HDFC Bank Limited executed on 18/10/2026 for financing the capital expenditure requirement ....
Intimation of Earnings Conference Call - Q2 & H1 FY 27
Jupiter Life Line Hospitals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve Unaudited Financial ....
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
Q1 FY27 Earnings Conference Call - Transcript
Outcome of Board Meeting dated July 31, 2026
The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Jupiter Life Line Hospitals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Unaudited Financial ....
Intimation of Earnings Conference Call - Q1 FY 27
Proceedings of the 24th Annual General Meeting of the Company (for detailed proceedings please refer the attached pdf)
We refer to our intimation dated May 15, 2026, and June 22, 2026, regarding the sub-division/split of the existing equity shares of the Company. In this regard, we wish to inform you that, ....
Voting Results and Scrutinizer's Report of the 24th Annual General Meeting of the Company
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026
Letter to Shareholders- Weblink of AGM Notice and Annual Report
Intimation of Closure of Trading Window.
Intimation of Newspaper Advertisement for the 24th Annual General Meeting of the Company to be held on Friday, July 17, 2026, through Video Conference (VC') /Other Audio-Visual Means ('OAVM').
Annual Report 2025-26
Annual Report 2025-26
Notice of the 24th Annual General Meeting of the Company will be held on Friday, July 17, 2026 at 11:00 A.M. IST through Video Conferencing/ Other Audio Visual Means ('VC/ OAVM')
Business Responsibility and Sustainability Report for the Financial year 2025-26.
Intimation of Newspaper Publication of the 24th Annual General Meeting of the Company to be held on Friday, July 17, 2026 through Video Conference ('VC') /Other Audio-Visual Means ('OAVM').
Q4 & FY 26 Earnings Conference Call - Transcript
Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')- Resignation of Chief Financial Officer
Audio Link of Analyst /Investor Conference call for Q4 & FY 26
Annual Secretarial Conpliance report for the year ended March 31, 2026
Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')- Resignation Letter of Dr. Bhaskar
Newspaper Publication for Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026
Intimation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') w.r.t. Resignation of Dr. Bhaskar Shah
Outcome of Board Meeting dated May 15, 2026, please refer the attached PDF for detailed information
Outcome of Board Meeting dated May 15, 2026, for detailed disclosure please refer the PDF
Intimation under Regulation 30 of the Listing Regulation
Record Date for Declaration of Interim Dividend
Considered and approved Sub- Division/Stock Split of the equity shares of the Company
InvInvestor Presentation for the quarter and year ended March 31, 2026estor Presentation
Jupiter Life Line Hospitals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2026 ,inter alia, to consider and approve Notice of the Board ....
Intimation of Earnings Conference Call - Q4 & FY26
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended March 31, 2026
The Company has received a letter from Mumbai Metropolitan Region Development Authority (MMRDA) conveying the acceptance of its tender for allotment of land on lease basis
Intimation of Closure of Trading Window for the quarter and year ending on March 31,2026.
Intimation regarding Credit Rating under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations)
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
Q3 & 9M FY26 Earnings Conference Call - Transcript
Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
Audio Link of Analyst/Investor Conference Call for Q3 and 9M FY26
Newspaper Publication for Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended December 31,2025.
Revised Investor Presentation for the quarter and nine months ended December 31,2025.
Credit Ratings
6Concalls
12Feb 2026
28 Feb 2026Jan 2026
31 Jan 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Oct 2023
31 Oct 2023Held by ETFs
3 ETFs hold JLHL · sorted by weight
Held by Mutual Funds
21 schemes hold JLHL · sorted by weight